Search Results
Your search for 3 matches 14971 pages
Showing 3701 - 3750Is Cabozantinib Active in Treating Brain Metastases From Renal Cell Carcinoma?
In a retrospective cohort study reported in JAMA Oncology, Hirsch et al found that cabozantinib showed substantial activity in treating brain metastases in patients with renal cell carcinoma. As stated by the investigators, “Patients with brain metastases from renal cell carcinoma have been...
Zanubrutinib for Relapsed or Refractory Marginal Zone Lymphoma
On September 14, 2021, the Bruton’s tyrosine kinase inhibitor zanubrutinib was granted accelerated approval for adults with relapsed or refractory marginal zone lymphoma (MZL) who have had at least one prior anti-CD20–based regimen.1 Supporting Efficacy Data Approval was based on findings in the...
MSK Launches New Center to Expand Commitment to Meeting the Unique Needs of Adolescents and Young Adults With Cancer
Although overall cancer cases are declining, they are on the rise in older adolescents and young adults (AYAs). Memorial Sloan Kettering Cancer Center (MSK) recently announced the establishment of the Lisa and Scott Stuart Center for Adolescent and Young Adult Cancers (the Stuart Center), expanding ...
Acupuncture vs Cognitive Behavioral Therapy for Cognitive Function in Cancer Survivors With Insomnia
Guest Editor’s Note: Cancer-related cognitive difficulties, experienced by many cancer survivors, include perceived or objective deficits in memory, attention, and concentration, which can negatively impact quality of life. Given the important role that healthful sleep plays in cognitive processes, ...
Cardio-oncology
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Urbanization in Bangladesh: The Prevalence of Breast Cancer Brings Unique Challenges
The number of deaths related to breast cancer are increasing at an alarming pace worldwide. According to a World Health Organization (WHO) 2020 report, approximately 2,088,849 new cases and 627,000 deaths related to breast cancer occurred in 2018.1 More than 55% of these deaths occurred in low- to ...
Memorial Sloan Kettering Cancer Center Announces New Early-Career Physician Research Program in Cancer Science
Memorial Sloan Kettering Cancer Center (MSK) recently announced a $25 million gift from Louis V. Gerstner, Jr, to create the Louis V. Gerstner, Jr Physician Scholars Program. Designed to support the innovative research of physician-scientists who are early in their career at MSK, the program will...
Mobocertinib for Previously Treated Advanced NSCLC With EGFR Exon 20 Insertion Mutations
On September 15, 2021, the kinase inhibitor mobocertinib was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for adults with locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by an FDA-approved test,...
Ruxolitinib for Chronic Graft-vs-Host Disease After Failure of Systemic Therapy
On September 22, 2021, ruxolitinib, a tyrosine kinase inhibitor of JAK1 and JAK2 was granted approval for treatment of chronic graft-vs-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients aged ≥ 12 years.1 Supporting Efficacy Data Approval was...
Noninferior Progression-Free Survival and Reduced Cardiovascular Toxicity With Acalabrutinib vs Ibrutinib in Previously Treated CLL
As reported in the Journal of Clinical Oncology by John C. Byrd, MD, of The Ohio State University Comprehensive Cancer Center, and colleagues, the phase III ELEVATE-RR trial has shown noninferior progression-free survival with the more-selective Bruton’s tyrosine kinase (BTK) inhibitor...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Bhutan
Located in the Eastern Himalayas, Bhutan is a landlocked, lower–middle-income country bordered by China and India. With a population of more than 850,000 people, Bhutan is predominately made up of three ethnic groups—the largest group is the Bhutia (also called Ngalop), followed by the Nepalese...
Cabozantinib for Previously Treated Advanced Differentiated Thyroid Cancer
On September 17, 2021, cabozantinib was approved for adult and pediatric patients aged ≥ 12 years with locally advanced or metastatic differentiated thyroid cancer progressing after VEGFR-targeted therapy and who are ineligible or refractory to radioactive iodine.1 Cabozantinib inhibits the...
Urge Congress to Avoid Shutdown, Increase Funding for Cancer Research in Fiscal Year 2022
ASCO is calling on Congress to continue its bipartisan support of federally funded research. Robust, sustained, and predictable funding growth for the National Institutes of Health (NIH) and the National Cancer Institute (NCI) baseline budgets is critical in advancing our nation’s work toward...
Financial Impact of Cardiovascular Disease and Cancer Care: Overlapping Toxicities
The leading causes of mortality in the United States are cardiovascular disease (23%) and cancer (21%), accounting for more than 40% of total deaths reported.1,2 The increasing rise in health-care expenditures over the past several decades has driven the need for metrics to further evaluate the...
Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer
On September 20, 2021, tisotumab vedotin-tftv, a tissue factor-directed antibody and microtubule inhibitor conjugate, was granted accelerated approval for the treatment of adults with recurrent or metastatic cervical cancer who have had disease progression on or after chemotherapy.1 Supporting...
Financial Toxicity Associated With Atherosclerotic Cardiovascular Disease, Cancer, and Both in U.S. Adult Patients
In a study of National Health Interview Survey (NHIS) data reported in JACC: CardioOncology, Javier Valero-Elizondo, MD, MPH, of Houston Methodist DeBakey Heart and Vascular Center, and colleagues, found that U.S. adult patients aged 18 to < 65 years with atherosclerotic cardiovascular disease...
POSEIDON Trial: Dual Checkpoint Blockade Plus Chemotherapy Improves Survival in First-Line Metastatic NSCLC
The combination of dual checkpoint inhibition plus chemotherapy could be the new standard of care in first-line metastatic non–small cell lung cancer (NSCLC), according to data presented during the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer.1 ...
Phase II Trial Finds Atezolizumab of Benefit in Patients With Lung Cancer and Brain Metastases
Patients with non–small cell lung cancer (NSCLC) and brain metastasis derived significant benefit from treatment with the monoclonal antibody atezolizumab plus chemotherapy, according to the multicenter phase II Atezo-Brain trial.1 The study was presented at the International Association for the...
Expert Point of View: J. Kellogg Parsons, MD, MHS, FACS
“Population-based screening for prostate cancer reduces prostate cancer mortality,” noted J. Kellogg Parsons, MD, MHS, FACS, Professor of Urology, UC San Diego Health, who commented on the study. “Effective screening programs focus on the early detection of aggressive but curable tumors, minimize...
STAMPEDE: In Nonmetastatic Castration-Sensitive Prostate Cancer, Abiraterone Added to Androgen-Deprivation Therapy Improves Survival
The addition of 2 years of abiraterone acetate plus prednisolone (AAP) to androgen-deprivation therapy improves metastasis-free survival and overall survival compared with androgen-deprivation therapy alone in men with nonmetastatic castration-sensitive prostate cancer, according to a primary...
Expert Point of View: Florian Lordick, MD, PhD
Florian Lordick, MD, PhD, Professor of Oncology and Director of the University Cancer Center Leipzig, Germany, applauded the positive finding for nivolumab plus chemotherapy in CheckMate 6491 and questioned why nivolumab plus ipilimumab did not meet its endpoint. “I’m calling this a big step...
CheckMate 649: Long-Term Data Support Nivolumab Plus Chemotherapy but Not Nivolumab Plus Ipilimumab in Gastric Cancer
Longer follow-up data from the phase III CheckMate 649 trial support the use of nivolumab plus chemotherapy as a new standard first-line regimen in patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. The findings were reported by Yelena Janjigian, ...
SECOMBIT Trial Evaluates Optimal Treatment Sequencing in BRAF-Mutated Melanoma
Patients with untreated, metastatic BRAF-mutated melanoma may benefit from receiving immunotherapy first, moving to targeted therapy in the second line, data from the updated overall survival analysis of the randomized, phase II SECOMBIT trial suggest.1 The study aimed to define the optimal...
Expert Point of View: Barbara Pistilli, MD
Barbara Pistilli, MD, of the Breast Cancer Group at Gustave Roussy Cancer Center, Villejuif, France, said the results of the TULIP trial, showing the progression-free survival benefit for vic-trastuzumab duocarmazine (SYD985), help to establish antibody-drug conjugates as key components of the...
Another Antibody-Drug Conjugate Enters the Metastatic Breast Cancer Landscape
In the global phase III TULIP trial in metastatic HER2-positive breast cancer, treatment with the antibody-drug conjugate vic-trastuzumab duocarmazine (SYD985) significantly improved progression-free survival in comparison with standard chemotherapy in previously treated patients, making this a new ...
Expert Point of View: Enrique Grande, MD
Invited discussant Enrique Grande, MD, of the Medical Oncology Department at MD Anderson Cancer Center Madrid, said that the VESPER trial should really be regarded as a neoadjuvant trial, since 88% of the patients enrolled were treated in the neoadjuvant setting. He focused the rest of his remarks ...
Neoadjuvant dd-MVAC Improves Local Control and Progression-Free Survival in Patients With Muscle-Invasive Bladder Cancer
The VESPER phase III trial answers some key questions regarding the optimal management of muscle-invasive bladder cancer. The study found that the neoadjuvant regimen of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) was superior to standard gemcitabine/cisplatin in...
Two Studies Examine the Efficacy of Immunotherapy for Leptomeningeal Carcinomatosis
Two new studies published in Nature Communications indicate that immunotherapy may benefit people with leptomeningeal carcinomatosis, a rare but serious complication of cancer that has spread to the brain and/or spinal cord. Approximately 5% to 8% of all patients with cancer develop leptomeningeal ...
National Cancer Act and Lung Cancer Screening: An Example of Intended Impact
The National Cancer Act of 1971 established a national priority to address the widely shared dread of a cancer diagnosis. The goal of the National Cancer Act was to strengthen the National Cancer Institute (NCI) to more effectively carry out the national effort against cancer. After the Act was...
BTK Inhibition in CLL: An Embarrassment of Riches
Chronic lymphocytic leukemia (CLL) is a B-cell lymphoproliferative disorder defined by a specific phenotype and the presence of more than 5,000 clonal B cells in the peripheral blood.1 In the absence of this number of circulating cells, its soft-tissue/bone-marrow counterpart is semantically...
Expert Point of View: Gonzalo Gomez-Abuin, MD, and Gabriel N. Hortobagyi, MD, MACP, FASCO
The invited discussant of the MONALESSA-2 trial was Gonzalo Gomez-Abuin, MD, a medical oncologist who is Head of the Clinical Research Unit at Hospital Alemán in Buenos Aires. According to Dr. Gomez-Abuin, phase III trials of three different CDK4/6 inhibitors—ribociclib, palbociclib, and...
MONALEESA-2: Overall Survival Benefit With First-Line Ribociclib Plus Letrozole
Ribociclib plus hormonal therapy in the first-line setting boosted overall survival by more than 1 year, vs hormone therapy alone, in postmenopausal women with hormone receptor–positive HER2-negative advanced breast cancer, according to the latest findings from the MONALEESA-2 trial, reported at...
Overall Survival in the MAIA Trial: Daratumumab, Lenalidomide, and Dexamethasone for Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma
As reported in The Lancet Oncology by Thierry Facon, MD, and colleagues, an interim analysis of overall survival in the pivotal phase III MAIA trial has shown a significant benefit with the addition of daratumumab to lenalidomide/dexamethasone in newly diagnosed, transplant-ineligible patients with ...
Addition of Liposomal Irinotecan to Fluorouracil and Leucovorin as Second-Line Treatment for Metastatic Biliary Tract Cancer
In a Korean phase IIb trial (NIFTY) reported in The Lancet Oncology, Yoo et al found that the addition of liposomal irinotecan to fluorouracil/leucovorin improved progression-free survival as a second-line treatment for patients with metastatic biliary tract cancer whose disease had progressed on...
Activity of Nab-sirolimus in Malignant Perivascular Epithelioid Cell Tumors
In the phase II AMPECT trial reported in the Journal of Clinical Oncology, Wagner et al found that the mTOR inhibitor nab-sirolimus produced a substantial rate of durable responses and a high disease control rate in patients with malignant perivascular epithelioid cell tumors. As stated by the...
Patients With Hematologic Malignancies: How Robust Is Their Immunity to SARS–CoV-2?
A large study from the United Kingdom has taken a deep dive into SARS–CoV-2 in the setting of cancer, yielding both concerning and encouraging findings about natural and vaccine-induced immunity. The study was presented at the Presidential Symposium during the European Society for Medical Oncology...
Relationship Between Preexisting TP53 CHIP Variants and Risk of Secondary Myeloid Neoplasms in High-Grade Ovarian Cancer
In a study reported in JAMA Oncology, Kwan et al found that preexisting TP53 clonal hematopoiesis of indeterminate potential (CHIP) variants were associated with increased risk of secondary myeloid neoplasms in patients receiving poly (ADP-ribose) polymerase (PARP) inhibitor therapy with rucaparib...
Mobocertinib for Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic NSCLC
In a phase I/II trial reported in JAMA Oncology, Caicun Zhou, PhD, MD, and colleagues found that mobocertinib, a first-in-class oral kinase inhibitor, produced durable responses in platinum-pretreated patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer (NSCLC). The...
Nivolumab/Low-Dose Ipilimumab Produces Responses in Patients With MSI-H/dMMR Metastatic Colorectal Cancer
As reported in the Journal of Clinical Oncology by Heinz-Josef Lenz, MD, and colleagues, in the phase II CheckMate 142 trial, first-line treatment with nivolumab plus low-dose ipilimumab produced a high rate of durable responses in a cohort of patients who had received no prior treatment for...
PARP Rechallenge Slows Ovarian Cancer Progression in Platinum-Sensitive Disease
Rechallenge with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in patients with platinum-sensitive ovarian cancer led to significant improvement in progression-free survival, in patients with either BRCA1/2-mutated or nonmutated (ie, wild-type) disease compared with placebo, according ...
Primary Tumor Resection Followed by Systemic Treatment vs Systemic Treatment Alone in Metastatic Colorectal Cancer: 60-Day Mortality
As reported in JAMA Surgery by van der Kruijssen et al, 60-day post–random assignment mortality results in the Danish/Dutch phase III CAIRO4 trial showed higher rates of mortality in patients with metastatic colorectal cancer who received primary tumor resection plus systemic treatment vs those...
First-Line Fulvestrant/Palbociclib vs Letrozole/Palbociclib for Endocrine-Sensitive, HR-Positive, HER2-Negative Advanced Breast Cancer
In the phase II PARSIFAL trial reported in JAMA Oncology, Antonio Llombart-Cussac, MD, and colleagues found that the combination of fulvestrant plus palbociclib did not improve progression-free survival vs letrozole plus palbociclib in women with advanced endocrine-sensitive, hormone receptor...
Global Analysis of National Health System Characteristics and Breast Cancer Mortality and Stage at Diagnosis
In a global population-based study reported in The Lancet Oncology, Duggan et al identified national health system characteristics associated with reduced breast cancer mortality, including higher Universal Health Coverage Service Coverage Index (UHC Index) rating and increased number of public...
Ibrutinib vs Placebo Following Achievement of Undetectable MRD With First-Line Ibrutinib/Venetoclax in CLL
As reported in the Journal of Clinical Oncology by William G. Wierda, MD, PhD, and colleagues, findings in the measurable residual disease (MRD) cohort of the phase II CAPTIVATE study indicated a high disease-free survival rate with placebo and no significant benefit of continued ibrutinib in...
DM-CHOC-PEN May Improve Outcomes for Adolescents and Young Adults With Central Nervous System Tumors
In a phase II clinical trial, the drug 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) improved survival for some adolescent and young adult patients with cancers involving the central nervous system, according to results presented by Morgan et al at the AACR-NCI-EORTC Virtual...
Abiraterone for Castration-Resistant, Androgen Receptor–Expressing Salivary Gland Cancer
In an Italian single-institution phase II trial reported in the Journal of Clinical Oncology, Locati et al found that abiraterone acetate showed activity in patients with androgen deprivation therapy (ADT)-resistant, androgen receptor (AR)-overexpressing salivary gland carcinoma. As stated by the...
Final Analysis of iNNOVATE: Addition of Ibrutinib to Rituximab for Waldenström’s Macroglobulinemia
As reported in the Journal of Clinical Oncology by Buske et al, the final analysis of the pivotal phase III iNNOVATE trial has shown a continued progression-free survival benefit with the addition of ibrutinib to rituximab in patients with Waldenström’s macroglobulinemia after 50 months of...
Nodal Recurrence With Sentinel Node Biopsy Alone Following Neoadjuvant Chemotherapy for Node-Positive Breast Cancer
In a single-center cohort study reported in JAMA Oncology, Barrio et al evaluated nodal recurrence rates in patients with clinically node-negative breast cancer following neoadjuvant chemotherapy for biopsy-proven node-positive disease. The investigators found an extremely low incidence of nodal...
Study Examines Potential Link Between Cancer and Physical Inactivity
A new report finds that more than 46,000 cancer cases annually in the United States could be prevented if Americans met the 5 hours per week of moderate-intensity activity recommended in the American Cancer Society’s physical activity guidelines. Recent findings published by Minihan et al in the...
FDA Approves Atezolizumab as Adjuvant Treatment for NSCLC
On October 15, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non–small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as...
